Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

The Clinical Course of Minimal Change Nephrotic Syndrome With Onset in Adulthood or Late Adolescence: A Case Series.

Maas RJ, Deegens JK, Beukhof JR, Reichert LJ, Ten Dam MA, Beutler JJ, van den Wall Bake AWL, Rensma PL, Konings CJ, Geerse DA, Feith GW, Van Kuijk WH, Wetzels JF.

Am J Kidney Dis. 2017 May;69(5):637-646. doi: 10.1053/j.ajkd.2016.10.032. Epub 2017 Jan 12.

PMID:
28089478
2.

The Effect of Online Hemodiafiltration on Infections: Results from the CONvective TRAnsport STudy.

den Hoedt CH, Grooteman MP, Bots ML, Blankestijn PJ, van der Tweel I, van der Weerd NC, Penne EL, Mazairac AH, Levesque R, ter Wee PM, Nubé MJ, van den Dorpel MA; CONTRAST investigators.

PLoS One. 2015 Aug 19;10(8):e0135908. doi: 10.1371/journal.pone.0135908. eCollection 2015.

3.

[Relationship between pre-dialysis period and mortality and morbidity; the importance of timely pre-dialysis care].

Laurens ST, Bex CG, Janssen L, Jeuken-Mertens SG, Luik AJ, Hermans MM, van Kuijk WH.

Ned Tijdschr Geneeskd. 2015;159:A8063. Dutch.

PMID:
26200420
4.

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*.

Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9.

5.

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators.

Clin J Am Soc Nephrol. 2015 May 7;10(5):791-9. doi: 10.2215/CJN.07730814. Epub 2015 Feb 20.

6.

Resistance to erythropoiesis stimulating agents in patients treated with online hemodiafiltration and ultrapure low-flux hemodialysis: results from a randomized controlled trial (CONTRAST).

van der Weerd NC, Den Hoedt CH, Blankestijn PJ, Bots ML, van den Dorpel MA, Lévesque R, Mazairac AH, Nubé MJ, Penne EL, ter Wee PM, Grooteman MP; CONTRAST Investigators.

PLoS One. 2014 Apr 17;9(4):e94434. doi: 10.1371/journal.pone.0094434. eCollection 2014.

7.

Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis.

den Hoedt CH, Bots ML, Grooteman MP, van der Weerd NC, Mazairac AH, Penne EL, Levesque R, ter Wee PM, Nubé MJ, Blankestijn PJ, van den Dorpel MA; CONTRAST Investigators.

Kidney Int. 2014 Aug;86(2):423-32. doi: 10.1038/ki.2014.9. Epub 2014 Feb 19.

PMID:
24552852
8.

Clinical predictors of decline in nutritional parameters over time in ESRD.

den Hoedt CH, Bots ML, Grooteman MP, van der Weerd NC, Penne EL, Mazairac AH, Levesque R, Blankestijn PJ, Nubé MJ, ter Wee PM, van den Dorpel MA; CONTRAST Investigators.

Clin J Am Soc Nephrol. 2014 Feb;9(2):318-25. doi: 10.2215/CJN.04470413. Epub 2014 Jan 23.

9.

The cost-utility of haemodiafiltration versus haemodialysis in the Convective Transport Study.

Mazairac AH, Blankestijn PJ, Grooteman MP, Penne EL, van der Weerd NC, den Hoedt CH, Buskens E, van den Dorpel MA, ter Wee PM, Nubé MJ, Bots ML, de Wit GA; CONTRAST investigators.

Nephrol Dial Transplant. 2013 Jul;28(7):1865-73. doi: 10.1093/ndt/gft045. Epub 2013 Jun 13.

PMID:
23766337
10.

Should we still focus that much on cardiovascular mortality in end stage renal disease patients? The CONvective TRAnsport STudy.

den Hoedt CH, Bots ML, Grooteman MP, Mazairac AH, Penne EL, van der Weerd NC, Ter Wee PM, Nubé MJ, Levesque R, Blankestijn PJ, van den Dorpel MA; CONTRAST investigators.

PLoS One. 2013 Apr 19;8(4):e61155. doi: 10.1371/journal.pone.0061155. Print 2013.

11.

New TRPC6 gain-of-function mutation in a non-consanguineous Dutch family with late-onset focal segmental glomerulosclerosis.

Hofstra JM, Lainez S, van Kuijk WH, Schoots J, Baltissen MP, Hoefsloot LH, Knoers NV, Berden JH, Bindels RJ, van der Vlag J, Hoenderop JG, Wetzels JF, Nijenhuis T.

Nephrol Dial Transplant. 2013 Jul;28(7):1830-8. doi: 10.1093/ndt/gfs572. Epub 2013 Jan 4.

PMID:
23291369
12.

Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients.

van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, Nubé MJ, Penne EL, Wetzels JF, Wiegerinck ET, Swinkels DW, Blankestijn PJ, Ter Wee PM; CONTRAST Investigators.

Nephrol Dial Transplant. 2013 Dec;28(12):3062-71. doi: 10.1093/ndt/gfs488. Epub 2012 Nov 11.

PMID:
23147161
13.

Effect of hemodiafiltration on quality of life over time.

Mazairac AH, de Wit GA, Grooteman MP, Penne EL, van der Weerd NC, den Hoedt CH, Lévesque R, van den Dorpel MA, Nubé MJ, ter Wee PM, Bots ML, Blankestijn PJ; CONTRAST Investigators.

Clin J Am Soc Nephrol. 2013 Jan;8(1):82-9. doi: 10.2215/CJN.00010112. Epub 2012 Nov 2.

14.

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS.

N Engl J Med. 2012 Dec 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624. Epub 2012 Nov 3.

15.

Poor compliance with guidelines on anemia treatment in a cohort of chronic hemodialysis patients.

van der Weerd NC, Grooteman MP, Blankestijn PJ, Mazairac AH, van den Dorpel MA, den Hoedt CH, Nubé MJ, Penne EL, van der Tweel I, Ter Wee PM, Bots ML; CONTRAST investigators.

Blood Purif. 2012;34(1):19-27. doi: 10.1159/000338919. Epub 2012 Aug 8.

PMID:
22889943
16.

Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents.

van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, Nubé MJ, Penne EL, Gaillard CA, Wetzels JF, Wiegerinck ET, Swinkels DW, Blankestijn PJ, Ter Wee PM; CONTRAST Investigators.

PLoS One. 2012;7(7):e39783. doi: 10.1371/journal.pone.0039783. Epub 2012 Jul 13.

17.

Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes.

Grooteman MP, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AH, den Hoedt CH, van der Tweel I, Lévesque R, Nubé MJ, ter Wee PM, Blankestijn PJ; CONTRAST Investigators.

J Am Soc Nephrol. 2012 Jun;23(6):1087-96. doi: 10.1681/ASN.2011121140. Epub 2012 Apr 26.

18.

Differences in quality of life of hemodialysis patients between dialysis centers.

Mazairac AH, Grooteman MP, Blankestijn PJ, Penne EL, van der Weerd NC, den Hoedt CH, van den Dorpel MA, Buskens E, Nubé MJ, ter Wee PM, de Wit GA, Bots ML; CONTRAST investigators.

Qual Life Res. 2012 Mar;21(2):299-307. doi: 10.1007/s11136-011-9942-3. Epub 2011 Jun 2. Erratum in: Qual Life Res. 2012 Mar;21(2):309. Lars Penne, E [corrected to Penne, E Lars].

19.

Changes in quality of life over time--Dutch haemodialysis patients and general population compared.

Mazairac AH, de Wit GA, Penne EL, van der Weerd NC, de Jong B, Grooteman MP, van den Dorpel MA, Buskens E, Dekker FW, Nubé MJ, Ter Wee PM, Boeschoten EW, Bots ML, Blankestijn PJ; CONTRAST investigators.

Nephrol Dial Transplant. 2011 Jun;26(6):1984-9. doi: 10.1093/ndt/gfq680. Epub 2010 Nov 4.

PMID:
21051503
20.

Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients.

Penne EL, van der Weerd NC, Grooteman MP, Mazairac AH, van den Dorpel MA, Nubé MJ, Bots ML, Lévesque R, ter Wee PM, Blankestijn PJ; CONTRAST investigators.

Clin J Am Soc Nephrol. 2011 Feb;6(2):281-9. doi: 10.2215/CJN.04480510. Epub 2010 Oct 28.

Supplemental Content

Loading ...
Support Center